Literature DB >> 11493449

Platelet glycoprotein V binds to collagen and participates in platelet adhesion and aggregation.

S Moog1, P Mangin, N Lenain, C Strassel, C Ravanat, S Schuhler, M Freund, M Santer, M Kahn, B Nieswandt, C Gachet, J P Cazenave, F Lanza.   

Abstract

Glycoprotein V (GPV) is a subunit of the platelet GPIb-V-IX receptor for von Willebrand factor and thrombin. GPV is cleaved from the platelet surface during activation by thrombin, but its role in hemostasis is still unknown. It is reported that GPV knockout mice had a decreased tendency to form arterial occluding thrombi in an intravital thrombosis model and abnormal platelet interaction with the subendothelium. In vitro, GPV-deficient platelets exhibited defective adhesion to a collagen type I-coated surface under flow or static conditions. Aggregation studies demonstrated a decreased response of the GPV-deficient platelets to collagen, reflected by an increased lag phase and reduced amplitude of aggregation. Responses to adenosine diphosphate, arachidonic acid, and the thromboxane analog U46619 were normal but were enhanced to low thrombin concentrations. The defect of GPV null platelets made them more sensitive to inhibition by the anti-GPVI monoclonal antibody (mAb) JAQ1, and this was also the case in aspirin- or apyrase-treated platelets. Moreover, an mAb (V.3) against the extracellular domain of human GPV selectively inhibited collagen-induced aggregation in human or rat platelets. V.3 injected in rats as a bolus decreased the ex vivo collagen aggregation response without affecting the platelet count. Finally, surface plasmon resonance studies demonstrated binding of recombinant soluble GPV on a collagen-coupled matrix. In conclusion, GPV binds to collagen and appears to be required for normal platelet responses to this agonist. (Blood. 2001;98:1038-1046)

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11493449     DOI: 10.1182/blood.v98.4.1038

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  19 in total

1.  Distinct roles of GPVI and integrin alpha(2)beta(1) in platelet shape change and aggregation induced by different collagens.

Authors:  Gavin E Jarvis; Ben T Atkinson; Daniel C Snell; Steve P Watson
Journal:  Br J Pharmacol       Date:  2002-09       Impact factor: 8.739

2.  Dynamic force spectroscopy of glycoprotein Ib-IX and von Willebrand factor.

Authors:  Maneesh Arya; Anatoly B Kolomeisky; Gabriel M Romo; Miguel A Cruz; José A López; Bahman Anvari
Journal:  Biophys J       Date:  2005-03-11       Impact factor: 4.033

3.  Is the mysterious platelet receptor GPV an unsuspected major target for platelet autoantibodies?

Authors:  Paquita Nurden; Alan T Nurden
Journal:  Haematologica       Date:  2019-06       Impact factor: 9.941

4.  In response to the comment by Hechler et al.: Amotosalen/UVA pathogen inactivation technology reduces platelet activatability, induces apoptosis and accelerates clearance.

Authors:  Simona Stivala; Sara Gobbato; Laura Infanti; Martin F Reiner; Nicole Bonetti; Sara C Meyer; Giovanni G Camici; Thomas F Lüscher; Andreas Buser; Juerg H Beer
Journal:  Haematologica       Date:  2017-12       Impact factor: 9.941

5.  PDK1 governs thromboxane generation and thrombosis in platelets by regulating activation of Raf1 in the MAPK pathway.

Authors:  B K Manne; P Münzer; R Badolia; B Walker-Allgaier; R A Campbell; E Middleton; A S Weyrich; S P Kunapuli; O Borst; M T Rondina
Journal:  J Thromb Haemost       Date:  2018-05-08       Impact factor: 5.824

6.  Assessment of Time-Dependent Platelet Activation Using Extracellular Vesicles, CD62P Exposure, and Soluble Glycoprotein V Content of Platelet Concentrates with Two Different Platelet Additive Solutions.

Authors:  Sami Valkonen; Birte Mallas; Ulla Impola; Anne Valkeajärvi; Juha Eronen; Kaija Javela; Pia R-M Siljander; Saara Laitinen
Journal:  Transfus Med Hemother       Date:  2019-05-07       Impact factor: 3.747

Review 7.  Thrombosis as an intravascular effector of innate immunity.

Authors:  Bernd Engelmann; Steffen Massberg
Journal:  Nat Rev Immunol       Date:  2012-12-07       Impact factor: 53.106

8.  Platelet IκB kinase-β deficiency increases mouse arterial neointima formation via delayed glycoprotein Ibα shedding.

Authors:  Shujian Wei; Huan Wang; Guoying Zhang; Ying Lu; Xiaofei An; Shumei Ren; Yunmei Wang; Yuguo Chen; James G White; Chunxiang Zhang; Daniel I Simon; Chaodong Wu; Zhenyu Li; Yuqing Huo
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-12-13       Impact factor: 8.311

Review 9.  Future innovations in anti-platelet therapies.

Authors:  N E Barrett; L Holbrook; S Jones; W J Kaiser; L A Moraes; R Rana; T Sage; R G Stanley; K L Tucker; B Wright; J M Gibbins
Journal:  Br J Pharmacol       Date:  2008-04-21       Impact factor: 8.739

Review 10.  Novel agents for anti-platelet therapy.

Authors:  Xuebin Ji; Ming Hou
Journal:  J Hematol Oncol       Date:  2011-11-04       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.